GSK 2849330

Drug Profile

GSK 2849330

Alternative Names: GSK-2849330

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2016 GlaxoSmithKline completes a phase I PET study for Solid tumours (Late-stage disease) in the Netherlands (NCT02345174)
  • 06 May 2016 Pharmacodynamics data from a preclinical study presented at the at 107th Annual Meeting of the American Association for Cancer Research(AACR-2016)
  • 11 Apr 2016 Phase-I development is ongoing in USA, Australia and Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top